Adamas Announces New Employment Inducement Grant
June 07, 2019 17:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 07, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new...
Adamas to Present at Upcoming JMP Investor Conference
June 03, 2019 16:31 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Pharmaceuticals Welcomes Vijay Shreedhar as Chief Commercial Officer
May 30, 2019 16:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas to Present at Upcoming BAML Investor Conference
May 13, 2019 11:14 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 13, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Reports First Quarter 2019 Financial Results
May 09, 2019 16:03 ET
|
Adamas Pharmaceuticals, Inc.
- First quarter net product sales of $11.7 million - GOCOVRI® total prescriptions grew to approximately 5,820 in Q1 2019 - Phase 3 study of ADS-5102 (GOCOVRI) in walking impairment in patients with...
Adamas to Announce First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019
May 02, 2019 16:05 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 first quarter financial results on Thursday, May 9,...
Adamas Announces New Employment Inducement Grant
March 12, 2019 16:05 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four...
Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018
March 04, 2019 16:35 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended...
Adamas to Present at Two Upcoming Investor Conferences
February 20, 2019 16:50 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019
February 20, 2019 16:49 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2018 financial results on...